Jefferies Upgrades BioCryst Pharma (BCRX) to Buy
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $4.65 -0.43%
Rating Summary:
17 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 50
Rating Summary:
17 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 50
Join SI Premium – FREE
Jefferies upgraded BioCryst Pharma (NASDAQ: BCRX) from Hold to Buy with a price target of $14.00 (from $10.00).
Analysts led by Brian Abrahams commented, "We are upgrading BCRX to Buy from Hold and increasing our target to $14 based on multiple 2016 opportunities for them to show increased competitiveness for their future HAE offerings, increasing long-term sales potential."
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $9.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Upgrades Barry Callebaut AG (BARN:SW) (BYCBF) to Buy
- HSBC Upgrades AMD (AMD) to Buy, 'AI TAM more than enough to go around'
- Piper Sandler Upgrades FB Financial (FBK) to Overweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot Upgrades, UpgradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
